Quabodepistat is under clinical development by Otsuka Pharmaceutical and currently in Phase II for Pulmonary Tuberculosis.

TBA-7371 is under development for the treatment of pulmonary tuberculosis caused by mycobacterium tuberculosis. The drug candidate is 1,4 azaindoles. It is administered through oral route in the form ...